Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
CompletedPhase 3NCT00763321
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary purpose of the study is to test the efficacy of 2 tablets (twice daily) of ABT-712, compared to placebo, administered over a 4-week period in participants with moderate to severe mechanical chronic low back pain (CLBP).
Study details
- Official title
- A Phase 3, Open-Label Period Followed by a Randomized, Double-blind Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain
- Conditions
- Interventions
- Drug: ABT-712
- Drug: Placebo
- Sponsor
- AbbVie (prior sponsor, Abbott)
- Organization
- AbbVie
- Start date
- 2008-09
- Primary completion
- 2009-04
- Sex
- All
- Age range
- from 21 Years to 75 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 31
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adult male and female subjects who voluntarily sign the informed consent * Diagnosis of CLBP of 6 months duration Exclusion Criteria: * Incapacitated or bedridden subjects * Subjects with history of surgical or invasive intervention
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00763321